2010 Highlights
-
Prevenar 13 for pediatric use has been launched in Nicaragua—the first developing nation to launch the new vaccine under the auspices of the Advance Market Commitment—within one year of its introduction in the U.S. and Europe. Previously, the gap between introduction of new vaccines in developed and developing countries averaged 15 years.
-
Children's Advil became, for the first time, the leading fever reducer and pain reliever for children.
-
Advil Congestion Relief became the first New Drug Application approval for the new Pfizer Consumer Healthcare. The remedy offers non-drowsy relief of sinus pressure, nasal swelling, congestion and headache. Consumers in the U.S. will now be able to choose between Advil Cold & Sinus, found behind the pharmacy counter, and Advil Congestion Relief, now available in the cough/cold aisle.
-
FluSure Pandemic received full licensure from the U.S. Department of Agriculture, making Pfizer the first company to gain conditional approval for an H1N1 vaccine for swine. The novel vaccine was developed in a record four-month time frame, anticipating the need to protect pigs following the outbreak of the H1N1 pandemic.
1
Our scope and reach encompass all stages of life—from infancy through the golden years, from human health and well-being to animal husbandry, from neglected diseases to scourges of modern life like cancer, pain, diabetes and heart disease.
We have been a leader in prescription medicines since our founding 160 years ago. Now we are also a global force in vaccines, consumer health care, infant nutrition and animal health. We aim to meet the full range of human need and help people around the world take control of, and manage, their health and well-being.
In the consumer marketplace, we keep finding new ways for our trusted remedies to bring comfort and support, such as the recently released Advil Congestion Relief and Caltrate Softchews, while Children's Advil and Centrum Ultra have risen to the top of their markets. Our nutrition line fills the gaps for children who need it, with new eye-health formulations and a new line for toddlers.
Perhaps the most significant news of 2010—certainly for children's health—has been our launch of Prevenar 13 (known as Prevnar 13 in the U.S.) which is once again revolutionizing child vaccines and had gained approval in 80 countries by year end.
